BackPropanc Biopharma Overview

Propanc Biopharma Receivables

Track Propanc Biopharma's receivables ($11K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$11056.00
204.32% YoYΔ $7423.00 vs prior year quarter

Peer trimmed avg / median

Loading

Propanc Biopharma Receivables History

Loading

Propanc Biopharma vs. peers: Receivables Comparison

Loading

Propanc Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Propanc Biopharma (PPCB) FAQ

As of the most recent data (March 2026), PPCB shows a receivables of $11K. That compares with $3.6K in the prior-year period — up 204.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PPCB's receivables is now $11K (was $3.6K) — a 204.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Propanc Biopharma is outperforming or lagging.

Tracking PPCB's receivables over time shows whether Propanc Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $11K That compares with $3.6K in the prior-year period — up 204.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Propanc Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $11K) with ownership activity and broader fundamentals.

Propanc Biopharma's receivables is $11K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.